Related Experiment Video

Updated: Dec 27, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Adenosine Inhibits Ovarian Cancer Growth Through Regulating RhoGDI2 Protein Expression

Bing Xia1, Jing Wang1

  • 1Hunan Cancer Hospital and the Affiliated Tumor Hospital of Xiang-Ya School of Medicine, Central South University, Changsha 410078, People's Republic of China.

Drug Design, Development and Therapy
|February 29, 2020
PubMed
Abstract

Insights

Adenosine (Ado) inhibits ovarian cancer growth by reducing tumor cell invasion and angiogenesis. This effect is dependent on Rho-specific guanine nucleotide dissociation inhibitor 2 (RhoGDI2) expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ovarian cancer remains a leading cause of cancer-related mortality.
  • Understanding novel therapeutic targets and mechanisms is crucial for improving treatment outcomes.

Purpose of the Study:

  • To investigate the anti-cancer effects of adenosine (Ado) on ovarian cancer.
  • To elucidate the underlying molecular mechanisms, focusing on Rho-specific guanine nucleotide dissociation inhibitor 2 (RhoGDI2) and angiogenesis.

Main Methods:

  • In vitro studies using A2780 human ovarian cancer cells (MTT assay, tube formation assay).
  • In vivo studies using a nude mouse xenograft model.
  • Immunohistochemistry (IHC) and Western blotting to assess protein expression (RhoGDI2, MMP-2, MMP-9, VEGF, TGF-β, TNF-α, CD31).
  • RhoGDI2 siRNA transfection to investigate its role.

Main Results:

  • Adenosine treatment inhibited ovarian cancer cell proliferation and tumor growth in vivo.
  • Adenosine significantly increased RhoGDI2 protein expression.
  • Down-regulation of RhoGDI2 attenuated adenosine's ability to suppress tumor cell invasion and angiogenesis.
  • Adenosine inhibited key angiogenic factors (MMP-2, MMP-9, VEGF, TGF-β, TNF-α, CD31), an effect reversed by RhoGDI2 interference.

Conclusions:

  • Adenosine exhibits anti-cancer properties against ovarian cancer by inhibiting tumor cell invasion and angiogenesis.
  • The mechanism is RhoGDI2-dependent, highlighting RhoGDI2 as a key mediator in adenosine's anti-tumor effects.
  • Adenosine represents a potential therapeutic agent for ovarian cancer, acting via modulation of RhoGDI2 and angiogenic pathways.
Keywords:
RhoGDI2adenosineangiogenesisgrowthinvasionovarian cancer

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
6.2K